Fig. 4: Tumour mutation burden (TMB) status. | npj Precision Oncology

Fig. 4: Tumour mutation burden (TMB) status.

From: High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population

Fig. 4: Tumour mutation burden (TMB) status.The alternative text for this image may have been generated using AI.

A 77/1166 (6.6%) of samples were TMB-high, with a median TMB of 5.2 mutations/Mb. Tumours of the lung (15.4%), endometrium (11.8%) and oesophagus (11.1%) had the highest proportions of TMB-high tumours. B Range of TMB scores (mutations/Mb) in the top 10 cancer types with highest proportion of TMB-high cases are shown.

Back to article page